Log in

Evolent Health Stock Forecast, Price & News

-0.22 (-1.79 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $12.08
50-Day Range
MA: $13.12
52-Week Range
Now: $12.08
Volume1.62 million shs
Average Volume1.44 million shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management. Its services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Read More
Evolent Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Management services



Sales & Book Value

Annual Sales$846.38 million
Cash Flow$2.22 per share
Book Value$10.98 per share


Net Income$-301,970,000.00


Market Cap$1.03 billion
Next Earnings Date11/3/2020 (Estimated)
-0.22 (-1.79 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVH News and Ratings via Email

Sign-up to receive the latest news and ratings for EVH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Evolent Health (NYSE:EVH) Frequently Asked Questions

How has Evolent Health's stock been impacted by COVID-19 (Coronavirus)?

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVH stock has increased by 74.6% and is now trading at $12.08.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Evolent Health?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolent Health

When is Evolent Health's next earnings date?

Evolent Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Evolent Health

How were Evolent Health's earnings last quarter?

Evolent Health Inc (NYSE:EVH) released its quarterly earnings results on Tuesday, August, 4th. The technology company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.14. The technology company earned $238.63 million during the quarter, compared to analysts' expectations of $241.05 million. Evolent Health had a negative return on equity of 4.68% and a negative net margin of 53.56%.
View Evolent Health's earnings history

What guidance has Evolent Health issued on next quarter's earnings?

Evolent Health updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $995M - 1.035 billion, compared to the consensus revenue estimate of $977.85 million.

What price target have analysts set for EVH?

11 analysts have issued 1-year price targets for Evolent Health's shares. Their forecasts range from $8.00 to $20.00. On average, they expect Evolent Health's share price to reach $13.56 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts' price targets for Evolent Health

Are investors shorting Evolent Health?

Evolent Health saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 12,070,000 shares, an increase of 10.9% from the August 15th total of 10,880,000 shares. Based on an average trading volume of 1,600,000 shares, the days-to-cover ratio is currently 7.5 days.
View Evolent Health's Short Interest

Who are some of Evolent Health's key competitors?

What other stocks do shareholders of Evolent Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Cisco Systems (CSCO), Micron Technology (MU), Energy Transfer LP Unit (ET) and Ford Motor (F).

Who are Evolent Health's key executives?

Evolent Health's management team includes the following people:
  • Mr. Frank J. Williams, Co-Founder, CEO & Chairman (Age 52)
  • Mr. Seth Blackley, Co-Founder, Pres & Director (Age 40)
  • Mr. Thomas Peterson III, Co-Founder & COO (Age 49)
  • Mr. Nicholas McGrane, Chief Financial Officer (Age 51)
  • Ms. Lydia Stone, VP, Chief Accounting Officer & Controller (Age 43)

When did Evolent Health IPO?

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is Evolent Health's stock symbol?

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Who are Evolent Health's major shareholders?

Evolent Health's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.41%), Bellevue Group AG (5.88%), Bank of New York Mellon Corp (2.22%), Silvercrest Asset Management Group LLC (2.10%), Formula Growth Ltd. (1.88%) and Glenmede Trust Co. NA (1.75%). Company insiders that own Evolent Health stock include Doug S Aron, Jonathan Weinberg, Kenneth A Samet, Michael D'amato and Seth Blackley.
View institutional ownership trends for Evolent Health

Which institutional investors are selling Evolent Health stock?

EVH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Glenmede Trust Co. NA, Goldman Sachs Group Inc., Gamco Investors INC. ET AL, Bank of America Corp DE, Formula Growth Ltd., Rock Point Advisors LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Evolent Health

Which institutional investors are buying Evolent Health stock?

EVH stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bellevue Group AG, Silvercrest Asset Management Group LLC, DC Investments Management LLC, Two Sigma Advisers LP, Vanguard Group Inc., Profit Investment Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley.
View insider buying and selling activity for Evolent Health

How do I buy shares of Evolent Health?

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evolent Health's stock price today?

One share of EVH stock can currently be purchased for approximately $12.08.

How big of a company is Evolent Health?

Evolent Health has a market capitalization of $1.03 billion and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Evolent Health employs 3,400 workers across the globe.

What is Evolent Health's official website?

The official website for Evolent Health is www.evolenthealth.com.

How can I contact Evolent Health?

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.